Clinical Trial Update: A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial of AUR 109 in ovarian cancer, colorectal cancer, and renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Ovarian Cancer
• Renal Cell Carcinoma

Drugs mentioned

• AUR 109

Snippet

Sponsor: Aurigene Discovery Technologies Limited | Conditions: Ovarian Cancer, Colorectal Cancer | Phase 2 | Status: TERMINATED